KBRA Assigns Preliminary Ratings to CSMC 2022-NQM2 Trust (CSMC 2022-NQM2)
NEW YORK–(BUSINESS WIRE)–KBRA assigns preliminary ratings to eight classes of mortgage pass-through notes from CSMC…
NEW YORK–(BUSINESS WIRE)–KBRA assigns preliminary ratings to eight classes of mortgage pass-through notes from CSMC…
SAN JOSE, Calif.–(BUSINESS WIRE)–Schrocken Inc. announced today that Bernie Prusaczyk has been appointed CEO of…
Del Ashley, Senior Director for Innovation at Inmarsat, appointed to the IoT Community Advisory Board…
ROSWELL, Ga.–(BUSINESS WIRE)–GS Yuasa Lithium Power (GYLP) announced today the successful completion of the Preliminary…
OmniLife’s integrated communication and clinical workflow management platform has been helping Transplant Centers streamline organ…
New Request for Ideas, the largest in the Foundation’s history, aims to support innovative ideas…
Enterprise Connect 2023 is Scheduled for March 27-30, 2023 in Orlando, FL SAN FRANCISCO–(BUSINESS WIRE)–Enterprise…
STRONGSVILLE, Ohio–(BUSINESS WIRE)–Union Home Mortgage (UHM), a high-growth independent mortgage banking company with a world-class…
Global research publisher and information analytics provider optimises contract lifecycle and reduces contract generation time…
The Liquidware and IGEL sponsored study shows how the rapid migration to work-from-home during COVID-19…
Company poised for continued growth in a $6+ billion market¹ RALEIGH, N.C., March 24, 2022…
DURHAM, N.C., March 24, 2022 (GLOBE NEWSWIRE) — Novan, Inc. (“the Company” or “Novan”) (Nasdaq:…
LAWRENCEVILLE, N.J., March 24, 2022 (GLOBE NEWSWIRE) — Celsion Corporation (NASDAQ: CLSN), a clinical-stage development company…
-Primary endpoint analysis expected early Q2 2022- -Final data expected Q2 2022- SAN DIEGO, March…
JERSEY CITY, N.J., March 24, 2022 (GLOBE NEWSWIRE) — SCYNEXIS, Inc. (NASDAQ: SCYX), a biotechnology…
CARLSBAD, Calif., March 24, 2022 (GLOBE NEWSWIRE) — Palisade Bio, Inc. (Nasdaq: PALI), a clinical…
Founder and CEO, Hing C. Wong, Ph.D., to be guest at “Fireside Chat” MIRAMAR, Fla.,…
NEW ORLEANS and LONDON, March 24, 2022 (GLOBE NEWSWIRE) — Revolo Biotherapeutics (“Revolo Bio” or…
Validive® Phase 2b/3 VOICE Trial Continues Adding Sites in the U.S. and Europe Camsirubicin Phase…
New interim data from TACTI-002 (Part B) evaluating the combination of efti and pembrolizumab in…